New clotting agent tested with common blood thinners
NCT ID NCT06517563
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early study tested an experimental drug called VMX-C001 in 16 healthy adults to see how it affects blood clotting when taken with or without common blood thinners. The goal was to measure changes in various clotting tests, not to treat any disease. Because it was a small, Phase 1 study in healthy people, it provides basic safety and activity data but does not suggest a treatment yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COAGULATION DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VMX-C001 (an engineered human clotting factor)
What this could lead to
If successful, this could help develop ways to manage bleeding in people taking certain blood thinners.
What could go wrong
This is a very early Phase 1 study in only 16 healthy people, so results may not apply to patients. It only measures lab markers, not real-world outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.